FLOTOR Pilot Study
Study Details
Study Description
Brief Summary
This is a non-randomised study assessing the technique of using indocyanine green as a fluorescent dye to highlight the thoracic duct during oesophectomy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
The thoracic duct is the largest vessel of the lymphatic system in the body. It transports chyle (a liquid containing both lymph and emulsified fats) from most of the body, including the gastrointestinal tract, into the left internal jugular vein. It is largely located in the thorax and is at risk of injury during the thoracic part of an oesophagectomy.
The reported incidence of thoracic duct injury during oesophagectomy is between 0.2 and 10.5%, although it may be under-reported in the literature. A review of prospective collected complication data from 292 consecutive oesophagectomies performed in Oxford over a 5 year period revealed a chyle leak rate of 9.9%. Chyle leak was associated in a doubling of median length of post-operative stay from 8 to 16 days in these patients. Chylothorax has been associated with a mortality of up to 30%.
Over the years, a number of attempts have been made to visualise chyle leakage following thoracic duct injury including administration of enteral fat containing feed (e.g. double cream), methylene blue and lymphoscintigraphy, but no studies have been published showing a mechanism to aid thoracic duct identification at the index operation, and so prevent injuries.
Fluorescence is a technique which uses fluorescent dyes (fluorophores) that emit invisible (near infra-red (NIR)) light when they are excited by light at a particular wavelength. In order to use this technique, a fluorescence-enabled camera is required in order to shine light at that particular wavelength on the fluorophore and to capture the light emitted. This is then displayed on a screen for the surgeon to see.
Indocyanine green (ICG) is a fluorescent molecule that is approved by the FDA (Food and Drug Administration) and the MHRA for use in humans. It is a widely used near infra-red dye for numerous operations. Near infra-red guided lymphatic mapping with ICG has gained much attention over recent years and its use has widely been published in breast and colorectal surgery. ICG has also been successfully used to identify the thoracic duct in a number of case reports in both adults and children.
ICG can be injected into the small bowel mesentery to aid identification of thoracic duct injury at re-exploration. This study aims to assess the feasibility of using ICG fluorescence to identify the thoracic duct during oesophagectomy, with the eventual aim of developing its routine use to prevent thoracic duct injuries.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mesenteric ICG Indocyanine green injected into the small bowel mesentery during oesophagectomy. |
Drug: Indocyanine Green
Fluorescent dye - indocyanine green
Other Names:
|
| Experimental: Feeding jejunostomy ICG (cream) Indocyanine green mixed with cream infiltrated into the feeding jejunostomy. |
Drug: Indocyanine Green
Fluorescent dye - indocyanine green
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of thoracic ducts seen under fluorescence versus number of thoracic ducts seen with white light. (Change over time) [0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose]
Thoracic duct visualised fluorescence assessment
Secondary Outcome Measures
- Signal to background ratio of fluorescence in thoracic ducts between 2 methods of ICG administration. [0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose]
Thoracic duct fluorescence levels between methods of ICG administration
- Signal to background ratio of fluorescence in thoracic ducts between dosing levels. [0, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 180, 240 minutes post dose]
Thoracic duct fluorescence levels between ICG doses
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant is willing and able to give informed consent for participation in the study.
-
Male or Female, aged 18 years or above.
-
Undergoing elective oesophagectomy
Exclusion Criteria:
-
Known allergy to iodine or ICG
-
Female patient who is pregnant, planning pregnancy or breastfeeding
-
Patient has a lactose intolerance (excluded only from receiving cream method)
-
Known significant liver failure
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Upper GI Surgery, Oxford University Hospitals | Headington | Oxfordshire | United Kingdom | OX3 7LE |
Sponsors and Collaborators
- Oxford University Hospitals NHS Trust
Investigators
- Principal Investigator: Richard Gillies, MBChB, Consultant Upper GI Surgeon
- Principal Investigator: Thomas Barnes, MBChB, Clinical Research Fellow
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 12968